Last reviewed · How we verify
Nang Kuang Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Smilon® | Smilon® | marketed | Calcium channel blocker | L-type calcium channels | Cardiovascular | |
| Dehypotin | Dehypotin | marketed | Other | |||
| Carbatin | Carbatin | marketed | Other |
Therapeutic area mix
- Other · 2
- Cardiovascular · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Addpharma Inc. · 1 shared drug class
- Ain Shams University · 1 shared drug class
- Bioprojet · 1 shared drug class
- Boryung Pharmaceutical Co., Ltd · 1 shared drug class
- Bristol-Myers Squibb · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- Handok Inc. · 1 shared drug class
- · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Nang Kuang Pharmaceutical Co., Ltd.:
- Nang Kuang Pharmaceutical Co., Ltd. pipeline updates — RSS
- Nang Kuang Pharmaceutical Co., Ltd. pipeline updates — Atom
- Nang Kuang Pharmaceutical Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Nang Kuang Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nang-kuang-pharmaceutical-co-ltd. Accessed 2026-05-17.